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Abstract
Malignant mesothelioma (MM) is rare and difficult to diagnose. Its identification de-
pends upon pathological investigation (cyto-histological assessment and immunohis-
tochemistry) supported by clinical and radiological evidence. In the last decade, the 
standardization of diagnostic methods has become a major focus of debate among pa-
thologists and clinicians. This has led to the writing of guidelines and recommendation 
for the diagnosis to achieve the goal of a standard diagnosis. In this article, a chronologi-
cal view relating to the pathological diagnosis of MM is presented together with a review 
of guidelines and recommendations.
INTRODUCTION
Malignant mesothelioma (MM) is a rare cancer de-
rived from the lining cells of serosal cavities. The pleura 
site outnumbers the peritoneum. Its identification 
depends upon pathological investigation supported 
by clinical and radiological evidence. To date, the ap-
proach to the diagnosis is based on cytological and his-
tological assessment and ancillary testing. The diagnosis 
can be very complex because MM is known for its com-
posite epithelial/mesenchymal patterns, its phenotypic 
variability from case to case, and its aptitude to mimic 
other cancers (particularly adenocarcinoma) or benign/
reactive processes. 
Experienced pathologists can identify the majority of 
cases beyond doubt. However, given the low frequency 
of this malignancy non-experienced pathologists may 
only encounter 1-3 cases a year in their routine, irrespec-
tive of his/her experience. The failure to identify MM 
or, viceversa, the misdiagnosis of MM in case of metas-
tasis has major implications at the individual level, and 
at public health level (bias in incidence and mortality 
estimates). Also, the diagnosis of MM carries important 
medico-legal implications, mainly related to compensa-
tion issues. In the last two decades, the improvement 
standardization of diagnostic methods has become a 
major focus of debate among pathologists and clinicians 
at local, and international level. This has led to the writ-
ing of guidelines and recommendation for the diagnosis 
to achieve the goal of a standard diagnosis.
In this article, a chronological perspective approach 
relating to the pathological diagnosis of MM is pre-
sented together with a review of guidelines and recom-
mendations. The role of immunohistochemistry and 
cytology is also briefly discussed. In closing, a focus 
on the Italian experience is provided. In Italy, asbes-
tos was widely used in many industries until the end 
of the 1980s and a nationwide surveillance system of 
MM incidence, the National Mesothelioma Register 
(ReNaM) (http://www.ispesl.it/renam/Index.asp) is op-
erating since 1993. Based on the literature in English 
as main language, basic textbooks or book sections and 
relevant peer-reviewed articles were taken into account 
as reference types.
PATHOLOGIC DIAGNOSIS OF MALIGNANT 
MESOTHELIOMA – CHRONOLOGY 
Since the seminal paper by Wagner et al. in 1960 [1], 
growing evidence of increased prevalence of MM in 
persons exposed to asbestos stimulated interest in the 
diagnosis of serosal tumors (Table 1). In standard pa-
thology textbooks, however, there was almost no men-
tion that this entity even existed. The identification of 
this cancer was a diagnosis of exclusion, after “painstak-
ing” post-mortem investigation of all organs to exclude 
a primary neoplastic growth elsewhere [2].
During the 1970s, pathologists were progressively ca-
pable to make a diagnosis of MM on the basis of histol-
ogy (hematoxylin-eosin stained sections), mucin histo-
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chemistry [3], and less rigorous exclusion of alternative 
tumors. In the mid-1970s, the ultrastructure of MM 
was described [4], and this proposed as a contribution 
tool to the diagnosis [4, 5]. In 1975, as part of a cohort 
mortality study for asbestos insulation workers, Irving J. 
Selikoff (1915-1992) the principal figure since the ear-
ly 1960s in establishing a causal relationship between 
exposure to asbestos and excess of mortality rates, in-
vited his colleague Yasunosuke Suzuki – at Mount Sinai 
Hospital in New York – to evaluate autopsy and biopsy 
samples obtained from deceased insulation workers. 
Professor Suzuki, the last member of the “Selikoff gen-
eration” (he passed away in 2011), initiated his system-
atic survey of MM cases that were confirmed as definite 
or probable in the diagnostic certainty by Suzuki him-
self, based on gross appearances, histology, histochem-
istry and electron microscopy [6]. In 1977, a report of 
a working group of experts for the Commission of the 
European Communities on the Public health risks of 
exposure to asbestos pointed out that the incidence 
of MM was underreported because many pathologists 
did not recognized the diagnosis [7]. The Commission 
recommended to set up Mesothelioma Registries in ac-
cordance with criteria as agreed upon by a “panel” of 
pathologists (designated as Mesothelioma Panel) that 
had as one of its basic objectives the standardization of 
the pathological diagnosis of mesothelioma. 
In 1983, the Council of the European Communities 
adopted the directive that Member States shall keep a 
register of recognized MM cases [8]. To assist in the 
establishment of MM registries, an atlas was prepared 
for the Commission of the European Communities in 
1985 [9]. During the 1980s, it was highlighted the im-
portance of a multi-technical approach to the patho-
logical diagnosis of MM with the employment of histo-
chemical and ultrastructural studies [10]. In parallel, it 
was provided evidence of the usefulness immunohisto-
chemistry as an aid in the differential diagnosis of MM 
[11] that included “negative” staining for carcinoem-
bryonic antigen (CEA), a “positive” carcinoma marker. 
The AFIP Atlas of Tumor Pathology on Tumors and 
pseudotumors of the serous membranes turned out one 
of the major reference textbook among pathologists 
[12]. Additional important reference were chapters in 
textbooks relating to pulmonary pathology [13] or to 
asbestos-related diseases [14].
In the 1990s, after the rapid growth in the application 
of immunohistochemistry, the AFIP Atlas was updated 
[15]. Moreover, WHO Pathology Panels promoted and 
proposed the adoption of a uniform diagnostic termi-
nology to classify mesothelial tumors [16], and many 
new books (and new editions) dealing with MM dedi-
cated specific sections on the pathology of MM [17-
19]. As well, pathologists were required to provide a re-
liable diagnosis of MM based on stringent criteria that 
included gross appearance, histology, histochemistry, 
immunohistochemistry and electron microscopy [20].
In the 2000s, it emerged the urgency of improving 
and standardizing diagnostic methods. Case series with 
pathological analysis of hundreds of MM cases were 
available [21]. In 2004, it was released the WHO classi-
fication of tumors of the pleura [22]; this book provides 
Table 1 
Pathological diagnosis of mesothelioma – Chronology 
Period Year (ref) Authors’ field Major area under discussion
1960s 1960 [1] Pathology Description of mesothelioma cases with crocidolite exposure
1967 [2] Pathology Diagnosis of mesothelioma is a diagnosis of exclusion (after exclusion of 
a primary cancer elsewhere)
1970s Diagnosis is made on the basis of histology (hematoxylin-eosin stained 
sections) and mucin histochemistry 
1977 [7] Commission of the European 
Communities on the Public 
Health Risks of Exposure to 
Asbestos 
Set up Mesothelioma Registries in accordance with criteria as agreed 
upon by a “panel” of pathologists (designated as Mesothelioma Panel) 
that had as one of its basic objectives the standardization of the 
pathological diagnosis of mesothelioma
1980s Multi-technical approach with the employment of histochemical 
and ultrastructural studies, as well as “negative” imunostaining for 
carcinoembryonic antigen (CEA), a “positive” carcinoma marker
1983 [8] Council of the European 
Communities 
Council directive: Member States shall keep a register of recognized 
mesothelioma cases 
1990s Rapid growth in the application of immunohistochemistry
1992 [6] Pathology Reliable diagnosis to be based on stringent criteria (gross appearance, 
histology, histochemistry, immunohistochemistry and electron 
microscopy) 
1999 [16] Pathology Pathology Panels of the WHO 
2000s Urgency of improving and standardizing diagnostic methods  – 
establishment of guidelines (see Table 2)
2004 [22] Pathology WHO classification of tumors of the pleura*
2006 [23] Pathology Pathology of MM by the International Mesothelioma Panel
*A new edition is in press (expected March 2015).
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an international standard for pathologists: diagnostic 
criteria, pathological features and all recognized MM 
variants including ICD-O codes were described. A new 
edition of the WHO classification of tumors of the pleu-
ra is being in press at the present (4th edition; expected 
March 2015). In 2006, the International Mesothelioma 
Panel published a volume on the pathology of MM [23] 
providing information about recent advances in meth-
ods for diagnosing this tumor; as well, it was available 
the third update of the AFIP Atlas [24]. In the same pe-
riod, several books were published involving groups of 
specialists; these volumes have sections devoted to MM 
pathology [25, 26]. Very recently a monograph book on 
MM has been released delivering a concise, updated 
review of the pathological characteristics of this malig-
nancy, WHO classification, mimicking conditions, and 
immunohistochemistry [27]. 
PATHOLOGIC DIAGNOSIS OF MALIGNANT 
MESOTHELIOMA – GUIDELINES AND 
RECOMMENDATIONS 
A systematic analysis of peer-reviewed articles regard-
ing guidelines and recommendations for the pathologi-
cal diagnosis of MM was performed in the PubMed 
electronic database. The search was conducted using 
the following search terms: mesothelioma AND diag-
nosis, and mesothelioma AND guidelines OR recommen-
dations in the advanced search page, encompassing 
the period 1960 to May 2014. Additional exploration 
included the term guideline in the specific search field 
“publication type”. Inclusion was confined to relevant 
papers in English and relevant non-English articles with 
English abstracts. Articles dealing with guidelines and/
or recommendations restricted to the radiological diag-
nosis or the treatment of MM were excluded.
Data from each study were extracted and organized 
into a summary table (Table 2). References refer mainly 
to pleural MM. These papers are written by clinicians 
or by a multidisciplinary team of experts or by societies 
with interest in the field of MM, with the aim for guid-
ance in various sectors including pathological diagnosis; 
others studies are entirely dedicated to the pathological 
aspects of diagnosis.
The first articles appeared in the late 1990s. In 
France, the product of a collaborative project by the 
Federation Nationale des Centres de Lutte Contre le 
Cancer (FNCLCC) [28] was the pronouncement that 
diagnosis should be based on multiple thoracoscopic 
Table 2 
Basic studies on pathological diagnosis of MM based on PubMed Search of the terms mesothelioma (title) AND recommendations 
(title) OR guidelines (title) OR as publication type (guidelines)
Year Publication type Reference Authors’ Country Topic Update
1998 FNCLCC Practice guidelines [28]1 France Standards, options and guidelines 2001 [32]1
1999 CAP Practice guidelines [29]2 USA Protocol for examination of specimens 
2001 BTS Consensus Development 
Conference 
[30]1 UK BTS Standards of Care Committee 
Statement including pathological 
diagnosis 
2007 [31]1
2005 ESMO Guidelines [33]1 Europe Recommendations on diagnosis 2007 [34]1 
2008 [35]1
2009 [36]1
2010 [37]1
2007 ADASP Practice guidelines [38]2 USA Recommendations for the reporting -
2009 IMIG Consensus Development 
Conference 
[39]2 USA, Canada, 
France, UK
Guidelines for pathologic diagnosis 2013 [40]2
2010 ERS/ESTS guidelines [41]1 Europe Recommendation for the management 
with a pathological point of view 
-
2011 Consensus Development 
Conference
[66]1 Italy First Italian Consensus Conference: expert 
opinions 
2013 ADRI 
Review article on guidelines
[42]1 Australia Guidelines for the diagnosis -
2013 Consensus Development 
Conference
[43]1 Italy Second Italian Consensus Conference 
on pleural MM: recommendations 
on management with a summary of 
pathology evidence 
20153
1 Reference relevant to all health personnel with an interest in the field
2 Reference relevant to pathologists
3 Third Italian Consensus Conference (www.aiom.it)
National Mesothelioma Register (ReNaM)
Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
College of American Pathologists (CAP) 
British Thoracic Society (BTS)  
European Society for Medical Oncoloogy (ESMO)
International Mesothelioma Interest Group (IMIG)
European Respiratory Society and the European Society of Thoracic Surgeons (ERS/ESTS)
Asbestos Diseases Research Institute (ADRI)
Association of Directors of Anatomic and Surgical Pathology (ADASP) 
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biopsies and immunostains (cytokeratin, EMA, vimen-
tin, CEA, and Leu-M1). In 1999, it was developed a 
document by the College of American Pathologists 
(CAP) as a tool to assist pathologists in the diagnostic 
process for the examination of specimens from patients 
with pleural MM. Use of this protocol (checklist) was 
intended to be entirely voluntary [29]. Immunohisto-
chemistry and electron microscopy were considered 
“important adjuncts to routine microscopic evaluation” 
but no other details were given.
In 2001, a multidisciplinary statement on MM guid-
ance (including pathological diagnosis) was offered by 
the British Thoracic Society (BTS) [30]. In 2007, an 
update statement was provided [31]. FNCLCC pub-
lished an update as well on recommendation relating 
to MM diagnosis based on the publication of new data 
[32]. In 2005, the European Society of Medical On-
cology (ESMO) Guidelines Task Force published the 
“Minimum clinical recommendations for diagnosis of 
malignant pleural mesotelioma” [33], and in the follow-
ing years various revisions were released [34-37].
In 2007, the Associations of Directors of Anatomic 
and Surgical Pathology (ADASP) published detailed 
guidelines for the reporting of pleural MM [38]. Fea-
tures optional for the final report (“specific institutional 
preference”) included among others the results of any 
ancillary study (histochemical, immunohistochemi-
cal and electron microscopy). Although immunohis-
tochemistry is routinely used to facilitate the diagno-
sis, ADSP does not prescribe a particular panel but 
recommends at least 2 positive mesothelial markers 
(calretinin, cytokeratins 5/6, D2-40 and WT-1) in con-
junction with at least 2 or more negative mesothelial 
markers (e.g. CEA, TTF-1, Ber-EP4 and MOC-31).
In 2009, the International Mesothelioma Interest 
Group (IMIG) provided a consensus statement relat-
ing to practical, broad guidelines meant to be “a refer-
ence for the pathologist for diagnosis of MM” [39]. An 
update by the original contributors and other patholo-
gists with expertise in the field was published in 2013 
[40]. Authors of these articles are pathologists from 
North America (Canada and USA), United Kingdom 
and France. The most important recommendations are 
use of histological features (including subtyping) and 
immunohistochemical panels. Another major point is 
that antibodies need to be used reflect the differential 
diagnosis in each case: in the typical epithelioid MM, 2 
mesothelioma markers and 2 carcinoma markers may 
be adequate to make a diagnosis; when there are unusu-
al findings, additional markers should be used. It is af-
firmed the limited usefulness of cytology, histochemical 
stains, and electron microscopy. For sarcomatoid MM, 
cytokeratins (AE1-AE3, CAM 5.2 and cytokeratin 7) 
are recommended. The pathologist should always take 
the clinical, radiologic, and pathologic features into 
consideration, and get expert second opinion in diffi-
cult cases.
In 2010, the European Respiratory Society and the 
European Society of Thoracic Surgeons (ERS/ESTS) 
included in their guidelines for the management of 
pleural MM also a section relating to the pathological 
diagnosis with recommendations concerning the use of 
WHO 2004 classification, and that a diagnosis of MM 
should always include immunohistochemistry with the 
guidelines of IMIG [41].
The last publications referring to 2013 together with 
the IMIG update [40] are Guidelines of the Asbestos 
Diseases Research Institute (ADRI) by a team of ex-
perts in Australia [42] and Recommendations of the 
Pathology Committee of Second Italian Consensus 
Conference on pleural MM [43]. The Australian team 
states that a “tissue specimen” is necessary to evaluate 
the mesothelial phenotype and invasion, and immuno-
istochemistry is essential for the diagnosis and should 
include negative and positive markers. The combina-
tion and number of antigens to evaluate is dependent 
on the differential diagnosis with calretinin, WT-1 and 
podoplanin (D2-40) being the more specific positive 
markers.
Recommendations of the Italian pathology commit-
tee include the following: cytology is a diagnostic tool 
for experienced cytopathologists and immunohisto-
chemistry should be based on the tumor subtype; for 
epithelial/mixed MM, 2 positive markers for mesothe-
lium always including calretinin and 2 carcinoma mark-
ers one being CEA; for sarcomatous MM broad spec-
trum cytokeratin are first-line antibodies [43].
THE ROLE OF IMMUNOHISTOCHEMISTRY
It is well recognized that MM evade definitive charac-
terization. There have been numerous attempts at try-
ing to determine not only histological criteria but also 
ancillary testing guidelines [44]. Immunohistochemis-
try has emerged as the most commonly used supple-
mentary procedure for its widespread availability. The 
antibody used depends on the histological subtype, the 
differential diagnosis, the site of the MM and the gen-
der of the patient. It usually consists of a combination 
of “positive” and “negative” mesothelial markers (anti-
body panels, Table 3) [40]. In the typical case of epi-
thelial MM, 2 mesothelioma markers and 2 carcinoma 
markers may be satisfactory. There are no established 
guidelines for the use of specific antibody panels. The 
selection of antibodies is related to the discretion of pa-
thologists on the basis of which ones works the best in 
a given laboratory, journal publications, review articles 
and specialized textbooks.
Current recommendations follow the ongoing discov-
ery of antibodies more specific for mesothelial cells and 
their commercial availability, since the late 1970ties. 
For example, the quite selective positive mesothelial 
marker calretinin was described in 1996 [45, 46] and 
its application in routine practice was realized after the 
late 1990s early 2000s. 
Summary of the data encompassing the period 1979-
2005 [47] documented that no single antibody is able 
to differentiate between adenocarcinoma and epitheli-
oid MM by immunohistochemistry; the use of a small 
panel of antibodies with a high combined sensitivity 
and specificity is recommended. After that time, several 
articles have proposed an enormous variety of rapidly 
changing markers as ancillary testing in the diagnosis of 
MM [48-50]. For that reason, an increase use of immu-
nostains has occurred in the past two decades in many 
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laboratories reflecting the acceptance of diagnostic 
panels, and the increasing availability of new antibodies 
[51]. Some investigators believe that single antibody or 
antibody pairs are equal or even better in efficacy when 
compared with more comprehensive pairs [44]. Others 
have validated minimal panels [52]. Recent reviews and 
update recommend compositions of panels of markers 
in various differential diagnosis [53, 54].
THE ROLE OF CYTOLOGY
Since most MM first present with effusions, cytologi-
cal analysis represents the primary diagnostic approach. 
However, cytological diagnosis of MM is notoriously 
challenging and of variable sensitivity [55, 56]. Whether 
cytology should be an acceptable means of diagnosing 
MM is as yet controversial among pathologists. In spite 
of this, its role is relevant because cytology may be the 
only source of pathological material available. In the 
summary of the IMIG guidelines it is stated that “there 
is limited usefulness of cytology”. However, the inter-
national community of cytopathologists has different 
consensus opinions and it is oriented in the reappraisal 
of this issue. An abstract entitled “Guidelines for cy-
topathologic diagnosis of malignant mesothelioma” has 
been discussed at the 2014 IMIG meeting (21-24 Oc-
tober 2014, Cape Town; http://imig2014.org/scientific-
programme/) and an article submitted to Cytopathology 
has been accepted for publication. In the recent Italian 
consensus conference, the pathology committee recom-
mended that cytology alone is a reliable diagnostic tool 
for “experienced cytopathologists”, with immunocyto-
chemical characterization [43]. 
THE ITALIAN EXPERIENCE
Among the initial articles by the Italian investiga-
tors, there are histological considerations and propos-
als about MM based on: morphological appearance in 
optical microscopy [57], epidemiological studies with 
reappraisal of histology with the purpose of confirming 
the diagnosis [58], surveys based on autopsy cases [59]. 
Later on there are interobserver variability studies to as-
sess consistency of pathological diagnosis on standard 
hematoxylin-eosin stained slides [60] and on hematox-
ylin-eosin and immunostained slides [61]. In the early 
1980s, two Italian pathologists contributed to the defi-
nition of the histogenesis of MM [62] and also inves-
tigated highly specific antimesothelial antibodies [63]. 
In 1996, a group of epidemiologists prepared the 
guidelines for the identification and definition of MM 
cases for their transmission from regional centers to 
the national mesothelioma Registry/ReNaM [64]. The 
update was released in 2004 [65]. A standard inter-
pretative grid allows a breakdown of cases into classes 
or groups depending on the degree of diagnostic ap-
proximation. Consistency controls have been fixed, i.e. 
criteria and procedures aimed at assessing diagnostic 
uniformity through a critical revision of the diagnoses 
received or recorded. The case classification provides 
for 5 groups and several subgroups of decreasing levels 
of diagnostic certainty, in relation to the procedure and 
diagnostic certainty achieved: 1) MM that is certain; 
2) probable MM; 3) possible MM; 4) MM “to be de-
fined”; 5) not MM. The classification of cases is based 
on pathology reports and diagnostic imaging (confirma-
tion of primary pleural or peritoneal neoplastic lesion 
and exclusion of alternative pathology), diagnosis of 
discharge of mesothelioma or similar assessment made 
by a clinician (MM probable and certain). The possible 
MM is characterized by indicative clinical and radio-
logical data, in the absence of cyto-histological exami-
nations. 
In 2008, the First Italian Consensus Conference on 
pleural MM was held that included a section on bio-
pathological evaluation [66] with specific indications. 
In 2011, at the Second Italian Consensus Conference 
on MM the pathology committee has proposed several 
recommendations, including as a first-line antibody 
battery two immohistochemical panels: 1) epithelioid/
mixed MM (2 mesothelioma positive markers, one be-
ing always calretinin, and 2 carcinoma markers, one be-
ing CEA); 2) sarcomatoid MM (use of broad spectrum 
cytokeratin) [43]. In January 2015, at the Third Italian 
Consensus Conference on pleural MM (www.aiom.it), 
the pathologic committee discussed the challenges in 
the diagnosis of non-epithelial MM (sarcomatoid or bi-
phasic variants), the guidelines for the cytological diag-
nosis of MM, and the need for standardized protocols 
for the pathology reporting of MM.
Table 3
Markers more often used in the diagnosis of mesothelioma
Epitheliod mesothelioma Sarcomatoid mesothelioma Markers differentiating mesothelioma vs 
reactive mesothelium1
Mesothelial markers Carcinoma markers
Calretinin CEA Cytokeratin 7 Desmin
Cytokeratin 5/6 TTF-1 Cytokeratin 8/18 EMA
HBME-1 CD15 (Leu-M1) Cytokeratin CAM5.2 p53
Podoplanin (D2-40) BG8 Cytokeratin AE1/AE3 GLUT-1
WT-1 B72.3 Cytokeratin MNF116 IMP3
Thrombomodulin MOC31 Cytokeratin 34BetaE12
Ber-EP4 Vimentin
E-cadherin
1 FISH for deletion of p16/CDKN2A.
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In 2012, the Italian Ministry of Health published a 
volume dedicated to the asbestos-related diseases with 
a chapter relating to MM (www.quadernidellasalute.it/
download/download/15-maggio-giugno-2012-quader-
no.pdf). 
CONCLUSIONS
Overall, general recommendations from different pa-
thologists worldwide agree upon the following (Table 4): 
guidelines are meant a practical reference for the pa-
thologists, not a directive. Adequate tissue samples in 
the typical context of clinical, radiological and surgical 
findings represent the gold standard for diagnosis. The 
first step in the diagnosis is the light microscopic exami-
nation of conventional stained preparations; immuno-
histochemical panels are essential part to the diagnosis; 
they are dependent on the site of the tumor and the 
gender of the patient, the phenotypic question (be-
nign versus malignant; epithelioid vesus non-epitheliod 
MM) and on reagents available in a given laboratory.
MM is diagnosed both in laboratories with no spe-
cific expertise in MM pathology and in those with 
experience for the presence of an ‘expert pathologist’ 
in the field. Since the 1960s, MM review panels have 
been implemented in several countries to validate the 
pathologic diagnosis of MM. Nowadays, this diagnosis 
is still problematic. Agreement among panel members 
has been reported around [60] and above 70% [40]. 
The rarity of this cancer, its medico-legal issues for in-
creasingly seek compensation and public health impli-
cations, and its prognosis in relation to histological sub-
type would deserve second expert opinion, particularly 
for difficult cases [67]. This implies a cost for the health 
system. However, appropriate referrals needs financial 
support that overall would be cost effective.
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Table 4
Pathologic diagnosis of malignant mesothelioma: general recommendations from different pathologists worldwide (October 
2014) 
Guidelines are meant as 
a practical reference for 
the pathologists, not a 
directive
Adequate tissue 
samples in the typical 
context of clinical, 
radiological and 
surgical findings 
represent the gold 
standard for diagnosis
The first step in the diagnosis 
is the light microscopic 
examination of conventional 
stained preparations
Immunohistochemical panels are essential part to 
the diagnosis: they are dependent on the site of 
the tumor and the gender of the patient
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